Diana Silverman1, Karen Ruth2, Elin R Sigurdson3, Brian L Egleston2, Lori J Goldstein4, Yu-Ning Wong4, Marcia Boraas3, Richard J Bleicher5. 1. Department of Surgery, Saint Francis Hospital and Health Center, Poughkeepsie, NY. 2. Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA. 3. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA. 4. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA. 5. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: richard.bleicher@fccc.edu.
Abstract
BACKGROUND: Nonmetastatic, noninflammatory, invasive breast cancers with skin involvement (SI) are classified as T4b, regardless of size. This study evaluated disease-specific survival (DSS) to determine whether size should be considered for these lesions rather than grouping them all into stage III. STUDY DESIGN: Surveillance, Epidemiology, and End Results data linked to Medicare claims were reviewed. Skin involved and non-SI tumors were reclassified using the American Joint Committee on Cancer, 7(th) edition groupings using tumor size and nodal involvement alone without considering SI (neostage). Disease-specific survival was adjusted for demographics, histology, and treatment using competing risk methods with propensity score-based weighting and bootstrap standard errors. RESULTS: Among 924 SI patients diagnosed between 1992 and 2005, tumors were 0.1 to 2.0 cm, 2.1 to 5.0 cm, and >5.0 cm in 11.6%, 51.1%, and 37.3% of patients, respectively. There were no nodal metastases in 22.3%, 1 to 3 positive nodes in 31.7%, 4 to 9 positive in 28.6%, and ≥10 positive in 17.4% of patients. For SI patients, adjusted 5-year DSS was 95.8% (95% CI, 95.6-96.0) for neostage I, declining progressively to 36.4% (95% CI, 33.8-39.2) for neostage IIIC patients. Adjusted 5-year DSS for SI and non-SI tumors (n = 66,185) was similar for neostage I, IIA, and IIB, and markedly lower for IIIA and IIIC. Adjusted DSS for SI IIIA was similar to non-SI IIIC. CONCLUSIONS: Noninflammatory SI breast cancers have widely varied DSS that differs by tumor size and nodal involvement and therefore should not all be stage III. Skin involvement should be subordinate to T and N groupings to classify SI with non-SI lesions having similar prognoses.
BACKGROUND: Nonmetastatic, noninflammatory, invasive breast cancers with skin involvement (SI) are classified as T4b, regardless of size. This study evaluated disease-specific survival (DSS) to determine whether size should be considered for these lesions rather than grouping them all into stage III. STUDY DESIGN: Surveillance, Epidemiology, and End Results data linked to Medicare claims were reviewed. Skin involved and non-SI tumors were reclassified using the American Joint Committee on Cancer, 7(th) edition groupings using tumor size and nodal involvement alone without considering SI (neostage). Disease-specific survival was adjusted for demographics, histology, and treatment using competing risk methods with propensity score-based weighting and bootstrap standard errors. RESULTS: Among 924 SI patients diagnosed between 1992 and 2005, tumors were 0.1 to 2.0 cm, 2.1 to 5.0 cm, and >5.0 cm in 11.6%, 51.1%, and 37.3% of patients, respectively. There were no nodalmetastases in 22.3%, 1 to 3 positive nodes in 31.7%, 4 to 9 positive in 28.6%, and ≥10 positive in 17.4% of patients. For SI patients, adjusted 5-year DSS was 95.8% (95% CI, 95.6-96.0) for neostage I, declining progressively to 36.4% (95% CI, 33.8-39.2) for neostage IIIC patients. Adjusted 5-year DSS for SI and non-SI tumors (n = 66,185) was similar for neostage I, IIA, and IIB, and markedly lower for IIIA and IIIC. Adjusted DSS for SI IIIA was similar to non-SI IIIC. CONCLUSIONS: Noninflammatory SI breast cancers have widely varied DSS that differs by tumor size and nodal involvement and therefore should not all be stage III. Skin involvement should be subordinate to T and N groupings to classify SI with non-SI lesions having similar prognoses.
Authors: Charles Cox; Barbara Centeno; Dan Dickson; John Clark; Santo Nicosia; Elisabeth Dupont; Harvey Greenberg; Nicholas Stowell; Laura White; Jayesh Patel; Ben Furman; Alan Cantor; Ardeshir Hakam; Nazeel Ahmad; Nils Diaz; Jeff King Journal: Cancer Date: 2005-02-25 Impact factor: 6.860
Authors: Richard J Bleicher; Karen Ruth; Elin R Sigurdson; Eric Ross; Yu-Ning Wong; Sameer A Patel; Marcia Boraas; Neal S Topham; Brian L Egleston Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-04-10 Impact factor: 44.544
Authors: Uwe Güth; Dorothy Jane Huang; Andreas Schötzau; Stephan Dirnhofer; Edward Wight; Gad Singer Journal: Breast Date: 2009-12-16 Impact factor: 4.380
Authors: Jim C Hu; Xiangmei Gu; Stuart R Lipsitz; Michael J Barry; Anthony V D'Amico; Aaron C Weinberg; Nancy L Keating Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: Nagi S El Saghir; Alexandru Eniu; Robert W Carlson; Zeba Aziz; Daniel Vorobiof; Gabriel N Hortobagyi Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Salvatore M Nardello; Nandani Kulkarni; Allison Aggon; Marcia Boraas; Elin R Sigurdson; Richard J Bleicher Journal: Am J Case Rep Date: 2015-03-14